Hennekam syndrome | |
---|---|
Other names | ennekam lymphangiectasia–lymphedema syndrome, intestinal lymphagiectasia–lymphedema–mental retardation syndrome [1] |
![]() | |
Hennekam syndrome is inherited in an autosomal recessive manner |
Hennekam syndrome also known as intestinal lymphagiectasia–lymphedema–mental retardation syndrome, [1] is an autosomal recessive disorder consisting of intestinal lymphangiectasia, facial anomalies, peripheral lymphedema, and mild to moderate levels of growth and intellectual disability. [1] [2]
It is also known as "lymphedema-lymphangiectasia-mental retardation syndrome". [3]
Hennekam Syndrome is subdivided according to the causative genetic lesion, most (or all) of which are affecting the VEGF-C/VEGFR-3 signaling pathway:
The first recognition of a genetic association was with CCBE1, published by its namesake, Raoul Hennekam. [7] The molecular mechanism of the lymphedema phenotype in CCBE1-associated cases was identified as a diminished ability of the mutated CCBE1 to accelerate and focus the activation of the primary lymphangiogenic growth factor VEGF-C. [8] Mutations in the FAT4 gene had previously been only associated with van Maldergem syndrome, but the pathogenetic molecular mechanism and the function of FAT4 within lymphangiogenesis are still unknown.
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)
Hennekam syndrome | |
---|---|
Other names | ennekam lymphangiectasia–lymphedema syndrome, intestinal lymphagiectasia–lymphedema–mental retardation syndrome [1] |
![]() | |
Hennekam syndrome is inherited in an autosomal recessive manner |
Hennekam syndrome also known as intestinal lymphagiectasia–lymphedema–mental retardation syndrome, [1] is an autosomal recessive disorder consisting of intestinal lymphangiectasia, facial anomalies, peripheral lymphedema, and mild to moderate levels of growth and intellectual disability. [1] [2]
It is also known as "lymphedema-lymphangiectasia-mental retardation syndrome". [3]
Hennekam Syndrome is subdivided according to the causative genetic lesion, most (or all) of which are affecting the VEGF-C/VEGFR-3 signaling pathway:
The first recognition of a genetic association was with CCBE1, published by its namesake, Raoul Hennekam. [7] The molecular mechanism of the lymphedema phenotype in CCBE1-associated cases was identified as a diminished ability of the mutated CCBE1 to accelerate and focus the activation of the primary lymphangiogenic growth factor VEGF-C. [8] Mutations in the FAT4 gene had previously been only associated with van Maldergem syndrome, but the pathogenetic molecular mechanism and the function of FAT4 within lymphangiogenesis are still unknown.
{{
cite journal}}
: CS1 maint: multiple names: authors list (
link)